Polarean Imaging
plc
("Polarean" or the "Company")
Virtual Investor Day
Polarean Imaging plc (AIM: POLX), a
commercial-stage medical imaging technology leader in advanced
Magnetic Resonance Imaging ("MRI") of lung function,
announces it will be hosting a
virtual investor day on Wednesday 12 March 2025, at 2.00pm GMT /
10.00am EDT.
The event will be
held via a Zoom webinar and will feature presentations on
Polarean's lung functional Xenon MRI platform, its current clinical
use at leading academic medical centres, as well as the Company's
expanded sales team and commercial strategy. The event is open to
all who wish to learn more about the story.
A welcome and
introduction will be given by Christopher von Jako,
Ph.D., CEO of Polarean.
The afternoon will also feature presentations by:
·
Dr. Laura
Walkup, Associate Professor, Cincinnati Children's
·
Dr. Alan
Huang, Vice President of Global Sales, Polarean
The presentations
will be followed by a Q&A session where attendees can submit
questions to the management team.
To register for
the webinar, please use this link:
Zoom Webinar - Register.
Enquiries:
|
Polarean Imaging
plc
|
www.polarean.com / www.polarean-ir.com
|
|
Christopher von Jako, Ph.D., Chief Executive
Officer
|
Via Walbrook PR
|
|
Charles Osborne, Chief Financial Officer
|
|
|
|
|
|
Stifel (NOMAD and
Sole Corporate Broker)
|
+44 (0)20 7710 7600
|
|
Nicholas Moore / Nick Harland / Ben Good
|
|
|
|
|
|
Walbrook
PR
|
Tel: +44 (0)20 7933 8780 or
polarean@walbrookpr.com
|
|
Anna Dunphy / Phillip Marriage
|
Mob: +44 (0)7876 741 001 /
+44 (0)7867 984 082
|
|
|
|
|
|
|
About
Polarean
Polarean is a
revenue-generating medical imaging technology company
revolutionising pulmonary medicine through direct visualisation of
lung function by introducing the power and safety of MRI to the
respiratory healthcare community. This community is in desperate
need of modern solutions to accurately assess lung function. The
Company strives to optimise lung health and prevent avoidable loss
by illuminating hidden disease, addressing the global unmet medical
needs of more than 500 million patients worldwide suffering from
chronic respiratory disease. Polarean is a leader in the field of
hyperpolarisation science and has successfully developed the first
and only hyperpolarised Xenon MRI inhaled contrast agent,
XENOVIEW®, which is now FDA-approved in the United States. Polarean
is dedicated to researching, developing, and commercialising
innovative imaging solutions with its non-invasive and
radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary
Xenon gas blend, gas hyperpolarisation system, as well as software
and accessories, facilitating fully integrated modern respiratory
imaging operations. Founded in 2012, with offices in Durham, NC,
and London, United Kingdom, Polarean is committed to increasing
global awareness of and broad access to its XENOVIEW MRI technology
platform. For the latest news and information about Polarean,
please visit www.polarean.com.
XENOVIEW IMPORTANT SAFETY
INFORMATION
Indication
XENOVIEW®,
prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized
contrast agent indicated for use with magnetic resonance imaging
(MRI) for evaluation of lung ventilation in adults and pediatric
patients aged 12 years and older.
Limitations of
Use
XENOVIEW has not
been evaluated for use with lung perfusion imaging.
CONTRAINDICATIONS
None.
Warnings and
Precautions
Risk of Decreased
Image Quality from Supplemental Oxygen: Supplemental oxygen
administered simultaneously with XENOVIEW inhalation can cause
degradation of image quality. For patients on supplemental oxygen,
withhold oxygen inhalation for two breaths prior to XENOVIEW
inhalation, and resume oxygen inhalation immediately following the
imaging breath hold.
Risk of Transient
Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause
transient hypoxemia in susceptible patients. Monitor all patients
for oxygen desaturation and symptoms of hypoxemia and treat as
clinically indicated.
Adverse
Reactions
Adverse Reactions
in Adult Patients: The adverse reactions (> one patient) in
efficacy trials were oropharyngeal pain, headache, and
dizziness. Adverse Reactions in Pediatric and Adolescent
Patients: In published literature in pediatric patients aged 6 to
18, transient adverse reactions were reported: blood oxygen
desaturation, heart rate elevation, numbness, tingling, dizziness,
and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient
increase in heart rate was reported following hyperpolarized xenon
Xe 129 administration. XENOVIEW is not approved for use in
pediatric patients less than 12 years of age.
Please see full
prescribing information at www.XENOVIEW.net
